

Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, June 23, 2020
Alfresa Holdings Corporation

**Notice regarding Capital Alliance between Alfresa Corporation
and Gene Therapy Research Institution Co., Ltd.**

A consolidated subsidiary, Alfresa Corporation (Head office: Chiyoda-ku, Tokyo; Representative Director & President: Yusuke Fukujin; hereafter “Alfresa”) subscribed to a part of new shares which Gene Therapy Research Institution Co., Ltd. (Head office: Kawasaki, Kanagawa; Representative Director & President: Katsutoshi Asai; hereafter “Gene Therapy Research Institution”) offered to raise capital in a third-party allotment, as specified below.

1. Purpose of the Capital Alliance

Gene therapy means an administration of genes or gene-introduced cells into the human body in order to treat or prevent diseases. One of the gene therapy treatment methods is that an objective gene is introduced into a target cell and it makes the transgene express. Various gene therapy techniques has been developed and utilized in actual treatment worldwide. In Japan, gene therapeutic agents covered by NHI's health insurance have started to be used in the clinical practices. Since adeno-associated viruses (hereafter “AAV”)* as vectors of objective genes has advantages of safety, durability and highly transgenic to various tissues in human, in the coming era for full-scaled gene therapy, it is expected and attracting worldwide attention to be applied to treat intractable or rare diseases.

Gene Therapy Research Institution is a Japanese company that researches and develops gene therapy, and develops and manufactures therapeutic agents. The company was established with the aim of penetrating innovative gene therapies, by using AAV as a vector for gene therapy (hereafter “AAV vector”), for intractable diseases for which there has ever been no effective treatment method.

AAV vectors under development by Gene Therapy Research Institution have high level of safety and gene expression efficiency to nerve cells and liver cells. In addition, it enables to get them express in a long-term and sustained manner. It is expected to be used as a new treatment method and to help relieve sufferings of patients of intractable or rare diseases such as sporadic amyotrophic lateral sclerosis (ALS) for which there has ever been no adequate treatment method.

Alfresa Group's 19-21 Mid-term Management Plan - *The Challenge of Further Growth “Together with Health, Together with Communities”* presents “Reform Business Models” as one of the Group

management policies, and the Group aims to expand its business fields by proactive investments for growth.

Through the capital alliance with Gene Therapy Research Institution, Alfresa will not only support AVV vector's commercialization, but collaborate on delivery method development and distribution of AAV vectors utilizing Alfresa's Tonomachi Regenerative Medicine Distribution Station.

* Adeno-associated virus (AAV): A highly safe virus with non-pathogenicity, inability to self-replicate, and very low potential to integrate into the chromosomes

2. Outline of the Capital Alliance (subscribing to a part of Gene Therapy Research Institution's third-party allotment of shares to raise capital)

The number of shares to be acquired	100 shares
Percentage of total shares issued	1.69%

3. Overview of Alliance Partner

(1) Corporate name	Gene Therapy Research Institution Co., Ltd.	
(2) Head office	3-25-22, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa	
(3) Title and name of representative	Katsutoshi Asai Representative Director & President	
(4) Description of business	Research and development of gene therapy, and development and manufacturing of therapeutic agents	
(5) Paid-in capital	387.5 million yen (as of May 2020)	
(6) Date of establishment	May 16, 2014	
(7) Relationship between a listed company and the company	Capital relationship	Not applicable.
	Human relationship	Not applicable.
	Transactional relationship	Not applicable.

About Alfresa Group

The Alfresa Group is a leader in Japanese healthcare industry which is dedicated to make its corporate philosophy “we create and deliver a fresh life for all” come true through a wide range of business lines including ethical pharmaceutical wholesaling, OTC drugs wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported its consolidated revenue of ¥2.7 trillion (US\$25 billion) for the fiscal year ended March 31, 2020. For more information, please see: <https://www.alfresa.com/eng/index.html>